

SUMO2/3 Antibody (C-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP1224a

Product Information

Application Primary Accession	IHC-P, WB, IF, E <u>P55854</u>
Other Accession	Q7SZ22, Q5XIF4, Q9Z172, Q6DI05, Q17QV3, P61959, P61958, P61957, Q2PFW2, P61956, Q6DHL4, Q6LDZ8, Q5ZJM9, P61955, Q6NV25, Q6GPW2, Q7ZTK7
Reactivity	Human, Rat, Mouse
Predicted	Xenopus, Zebrafish, Bovine, Chicken, Hamster, Monkey, Pig, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	11637
Antigen Region	49-81

Additional Information

Gene ID	6612
Other Names	Small ubiquitin-related modifier 3, SUMO-3, SMT3 homolog 1 {ECO:0000312 HGNC:HGNC:11124}, SUMO-2, Ubiquitin-like protein SMT3A, Smt3A, SUMO3 (<u>HGNC:11124</u>)
Target/Specificity	This SUMO2/3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 49-81 amino acids from the C-terminal region of human SUMO2/3.
Dilution	IHC-P~~1:100~500 WB~~1:1000 IF~~1:100 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	SUMO2/3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name

Ubiquitin-like protein which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Does not seem to be involved in protein degradation and may function as an antagonist of ubiquitin in the degradation process. Plays a role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2 or CBX4 (PubMed: <u>11451954</u> , PubMed: <u>18538659</u> , PubMed: <u>21965678</u>). Plays a role in the regulation of sumoylation status of SETX (PubMed: <u>24105744</u>).
Cytoplasm. Nucleus. Nucleus, PML body
Expressed predominantly in liver.

Background

SUMO2 and SUMO3 are members of the SUMO (small ubiquitin-like modifier) protein family. This protein family functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. However, unlike ubiquitin which targets proteins for degradation, this protein is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. In vertebrates, three members of the SUMO family have been described, SUMO 1 and the functionally distinct homologues SUMO 2 and SUMO 3. SUMO modification sites present in the N terminal regions of SUMO 2 and SUMO 3 are utilized by SAE1/SAE2 (SUMO E1) and Ubc9 (SUMO E2) to form polymeric chains of SUMO 2 and SUMO 3 on protein substrates, a property not shared by SUMO 1.

References

Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002). Lapenta, V., et al., Genomics 40(2):362-366 (1997).

Images



All lanes : Anti-SUMO2/3 Antibody (C-term) at 1:2000 dilution Lane 1: SH-SY5Y whole cell lysate Lane 2: Hela whole cell lysate Lane 3: Jurkat whole cell lysate Lane 4: HL-60 whole cell lysate Lane 5: Mouse cerebellum tissue lysate Lane 6: Mouse liver tissue lysate Lane 7: Rat liver tissue lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 12 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.



Citations

- TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson's Disease
- The SUMOylation landscape of renal cortical collecting duct cells.
- HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.
- TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
- Adenovirus E4-ORF3 Targets PIAS3 and Together with E1B-55K Remodels SUMO Interactions in the Nucleus and at Virus Genome Replication Domains.
- Signaling via the IL-20 receptor inhibits cutaneous production of IL-1β and IL-17A to promote infection with methicillin-resistant Staphylococcus aureus.
- PKC III mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation.
- Lysine deacetylation in ischaemic preconditioning: the role of SIRT1.
- Keratin hypersumoylation alters filament dynamics and is a marker for human liver disease and keratin mutation.
- <u>Neuroprotection resulting from insufficiency of RANBP2 is associated with the modulation of protein and lipid</u> <u>homeostasis of functionally diverse but linked pathways in response to oxidative stress.</u>
- Spatial interplay between PIASy and FIP200 in the regulation of signal transduction and transcriptional activity.
- SUMO modification of the Ets-related transcription factor ERM inhibits its transcriptional activity.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.